John Yu

ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.

Cedars-Sinai Medical Center operates a hospital that provides healthcare services. It specializes in cancer, endocrinology, gynecology, neurology, orthopedics, and respiratory disorders. The company was founded in 1902 and is headquartered in Los Angeles, CA.

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.